Hospital Universitari Quiron Dexeus - Servicio de Oncologia Medica

Barcelona 08028

0 studies enrolling now · 3 studies all time

What they study most

Non-small Cell Lung Cancer

Studies at this site

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) — Running, not enrolling
• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) — Completed
• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) — Stopped early